Kairos Pharma, LTD.
Develops oncology therapies targeting drug resistance and immune suppression.
KAPA | US
Overview
Corporate Details
- ISIN(s):
- US48301N1046
- LEI:
- Country:
- United States of America
- Address:
- 2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
- Website:
- https://kairospharma.com
Description
Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics. The company's primary focus is on overcoming key hurdles in cancer treatment, specifically drug resistance and immune suppression. Its lead product candidate, ENV105, is an antibody that targets the CD105 protein to reverse resistance to existing cancer drugs. ENV105 is in mid-stage clinical trials for prostate cancer and early-stage trials for lung cancer. In addition, Kairos is developing a pipeline of immunotherapies designed to reverse cancer-induced immune suppression. This includes KROS101, a small molecule to enhance T cell activity, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma, for which an Investigational New Drug (IND) application has been cleared.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kairos Pharma, LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
